Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona“) is pleased to announce the voting results from its Annual General Meeting of Shareholders (the “Meeting”), held in Vancouver, British Columbia on November 10, 2021. The total number of shares represented by shareholders present in person and by proxy at the meeting was 33,335,079, representing 14.45% of Sirona’s issued and outstanding Common Shares.
All matters put forward to shareholders for consideration and approval, as set out in the Company’s Management Information Circular dated 12th of October, 2021, were approved by the requisite majority of votes cast at the Meeting. These were:
1. To elect Sirona’s board of directors; 2. to fix the number of directors of the Company at five; 3. to appoint DeVisser Gray LLP, Chartered Professional Accountants, as the Company’s auditor for the ensuing year and authorize the directors to set the auditor’s remuneration; and 4. to confirm and approve the Company’s existing stock option plan.
“We thank our shareholders for their participation and continued support,” said Dr. Howard Verrico, CEO of Sirona. “We look forward to further building and commercializing our pipeline.”
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.